About Immunicon
Immunicon is a company based in Bryn Athyn (United States) founded in 1983 by Paul Liberti was acquired by CellSearch in June 2008.. Immunicon has raised $75.35 million across 5 funding rounds from investors including NIH, LHC Group and Canaan. Immunicon operates in a competitive market with competitors including NanoCellect Biomedical, ThinkCyte, Singulex, Cell Microsystems and Silicon Biosystems, among others.
- Headquarter Bryn Athyn, United States
- Founders Paul Liberti
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$75.35 M (USD)
in 5 rounds
-
Latest Funding Round
$940 K (USD), Grant
Jun 01, 2015
-
Investors
NIH
& 11 more
-
Employee Count
Employee Count
-
Acquired by
CellSearch
(Jun 11, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Immunicon
Immunicon has successfully raised a total of $75.35M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $940 thousand completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Grant — $940,000
-
First Round
First Round
(11 Sep 2000)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2015 | Amount | Grant - Immunicon | Valuation |
investors |
|
| Apr, 2008 | Amount | Grant - Immunicon | Valuation |
investors |
|
| Jul, 2003 | Amount | Series F - Immunicon | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immunicon
Immunicon has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, LHC Group and Canaan. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech-based companies are invested in by Wheatley Partners.
|
Founded Year | Domain | Location | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Founded Year | Domain | Location | |
|
Early-stage tech startups are funded by this venture capital firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immunicon
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Immunicon
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunicon Comparisons
Competitors of Immunicon
Immunicon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NanoCellect Biomedical, ThinkCyte, Singulex, Cell Microsystems and Silicon Biosystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Develops flow cytometry and cell sorting technology
|
|
| domain | founded_year | HQ Location |
Cell analysis and sorting technologies are developed with AI integration.
|
|
| domain | founded_year | HQ Location |
Single-molecule counting technology is developed for cardiovascular biomarker detection.
|
|
| domain | founded_year | HQ Location |
Developer of a technology to isolate and recover single cells for molecular analysis
|
|
| domain | founded_year | HQ Location |
Lab-on-a-chip technologies for miniaturized cell-biology testing are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Immunicon
When was Immunicon founded?
Immunicon was founded in 1983 and raised its 1st funding round 17 years after it was founded.
Where is Immunicon located?
Immunicon is headquartered in Bryn Athyn, United States. It is registered at Bryn Athyn, Pennsylvania, United States.
Is Immunicon a funded company?
Immunicon is a funded company, having raised a total of $75.35M across 5 funding rounds to date. The company's 1st funding round was a Series F of $24.75M, raised on Sep 11, 2000.
What does Immunicon do?
Founded in 1983 in Bryn Athyn, United States, Immunicon focused on biotechnology for cancer disease management. Platform technologies were developed to identify and characterize rare cells in blood, such as circulating tumor cells. Diagnostic and research products were commercialized, while analytical services were provided to pharmaceutical and biotechnology firms for therapeutic development. The company was acquired by Veridex in August 2008.
Who are the top competitors of Immunicon?
Immunicon's top competitors include NanoCellect Biomedical, ThinkCyte and Silicon Biosystems.
Who are Immunicon's investors?
Immunicon has 12 investors. Key investors include NIH, LHC Group, Canaan, Burrill and Company, and CellSearch.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.